AngioDynamics (NSDQ:ANGO) said today it acquired Surgical Specialties’ BioSentry Tract Sealant assets for an undisclosed amount, and touted a recent legal win in a case against Becton Dickinson & Co. (NYSE:BDX) subsidiary C.R. Bard.
The newly acquired BioSentry system is designed to prevent the occurrence of pneurmothorax during CT-guided percutaneous lung biopsies using a proprietary hydrogel plug which prevents air leakage during the procedure. The sealant has both FDA clearance and CE Mark approval in the European Union.
As part of the acquisition, AngioDynamics said that Surgical Specialties’ 12-person commercial organization will join the company as part of its oncology business.
“The addition of the BioSentry technology to our oncology portfolio is the type of strategic and thoughtful acquisition that aligns with our plans to deliver safer, clinically relevant, and economically favorable solutions that improve patient outcomes. By expanding our offerings in the oncology discipline, we are creating an opportunity to serve patients who may also benefit from our core products earlier in their disease state,” prez & CEO Jim Clemmer said in a press release.
The company also touted a legal win after a federal judge in New York denied a motion from BD’s Bard to dismiss an antitrust lawsuit filed by AngioDynamics alleging unfair competition, allowing AngioDynamic’s suit to proceed forward.
The post AngioDynamics acquires Surgical Specialties’ BioSentry sealant, updates on Bard antitrust suit appeared first on MassDevice.